{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:15:46Z","timestamp":1790741746269,"version":"4.1.0"},"reference-count":269,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41569-025-01171-w","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T07:42:00Z","timestamp":1749109320000},"page":"39-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular involvement in glycogen storage diseases"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4379-0917","authenticated-orcid":false,"given":"Tom\u00e0s","family":"Pin\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-3600","authenticated-orcid":false,"given":"Richard M.","family":"Cubbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9418-0564","authenticated-orcid":false,"given":"Alfredo","family":"Santalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-7007","authenticated-orcid":false,"given":"Carmen","family":"Fiuza-Luces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-3583","authenticated-orcid":false,"given":"Alejandro","family":"Santos-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4741-772X","authenticated-orcid":false,"given":"Miguel A.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2877-5049","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-3094","authenticated-orcid":false,"given":"Joachim","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9060-4139","authenticated-orcid":false,"given":"Niels","family":"\u00d8rtenblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-0997","authenticated-orcid":false,"given":"Alejandro","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"1171_CR1","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.3748\/wjg.v29.i25.3932","volume":"29","author":"E Gumus","year":"2023","unstructured":"Gumus, E. & Ozen, H. Glycogen storage diseases: an update. World J. Gastroenterol. 29, 3932\u20133963 (2023).","journal-title":"World J. Gastroenterol."},{"key":"1171_CR2","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.1128\/MCB.24.16.7179-7187.2004","volume":"24","author":"BA Pederson","year":"2004","unstructured":"Pederson, B. A. et al. Abnormal cardiac development in the absence of heart glycogen. Mol. Cell Biol. 24, 7179\u20137187 (2004).","journal-title":"Mol. Cell Biol."},{"key":"1171_CR3","unstructured":"ESC Working Group on Myocardial and Pericardial Diseases. Diagnosis and management of cardiac manifestations in Anderson Fabry disease and glycogen storage diseases. European Society of Cardiology https:\/\/www.escardio.org\/static-file\/Escardio\/Subspecialty\/Working%20Groups\/Myocardial%20and%20Pericardial%20Diseases\/y.%20Documents\/Booklet-WG-Diseases-Fabry&Glycogen.pdf (2025)."},{"key":"1171_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.nmd.2011.08.008","volume":"22","author":"S Sukigara","year":"2012","unstructured":"Sukigara, S. et al. Muscle glycogen storage disease 0 presenting recurrent syncope with weakness and myalgia. Neuromuscul. Disord. 22, 162\u2013165 (2012).","journal-title":"Neuromuscul. Disord."},{"key":"1171_CR5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa066691","volume":"357","author":"G Kollberg","year":"2007","unstructured":"Kollberg, G. et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N. Engl. J. Med. 357, 1507\u20131514 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1171_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ymgme.2009.07.012","volume":"98","author":"JM Cameron","year":"2009","unstructured":"Cameron, J. M. et al. Identification of a novel mutation in GYS1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts. Mol. Genet. Metab. 98, 378\u2013382 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"1171_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.nmd.2022.03.008","volume":"32","author":"O Musumeci","year":"2022","unstructured":"Musumeci, O. et al. A new phenotype of muscle glycogen synthase deficiency (GSD0B) characterized by an adult onset myopathy without cardiomyopathy. Neuromuscul. Disord. 32, 582\u2013589 (2022).","journal-title":"Neuromuscul. Disord."},{"key":"1171_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.128","volume":"16","author":"PS Kishnani","year":"2014","unstructured":"Kishnani, P. S. et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet. Med. 16, e1 (2014).","journal-title":"Genet. Med."},{"key":"1171_CR9","unstructured":"Bali D. S. et al. Glycogen Storage Disease Type I (eds Adam M. P. et al.) www.ncbi.nlm.nih.gov\/books\/NBK1312\/ (GeneReviews, 2021)."},{"key":"1171_CR10","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/sj.ki.5002718","volume":"73","author":"WH Yiu","year":"2008","unstructured":"Yiu, W. H. et al. Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia. Kidney Int. 73, 716\u2013723 (2008).","journal-title":"Kidney Int."},{"key":"1171_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0272-6386(88)80160-4","volume":"11","author":"AJ Jonas","year":"1988","unstructured":"Jonas, A. J., Verani, R. R., Howell, R. R. & Conley, S. B. Hypertension in a child with type IA glycogen storage disease. Am. J. Kidney Dis. 11, 264\u2013266 (1988).","journal-title":"Am. J. Kidney Dis."},{"key":"1171_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s12098-015-1732-4","volume":"82","author":"E Bhowmik","year":"2015","unstructured":"Bhowmik, E., Ghosh, M., Sabui, T. K. & Mondal, R. Glycogen storage disease type I presenting with hypertension during infancy. Indian J. Pediatr. 82, 767 (2015).","journal-title":"Indian J. Pediatr."},{"key":"1171_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJM198801073180102","volume":"318","author":"YT Chen","year":"1988","unstructured":"Chen, Y. T., Coleman, R. A., Scheinman, J. I., Kolbeck, P. C. & Sidbury, J. B. Renal disease in type I glycogen storage disease. N. Engl. J. Med. 318, 7\u201311 (1988).","journal-title":"N. Engl. J. Med."},{"key":"1171_CR14","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1007\/BF02679990","volume":"161","author":"JP Rake","year":"2002","unstructured":"Rake, J. P. et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. results of the European Study on Glycogen Storage Disease type I (ESGSD I). Eur. J. Pediatr. 161, S20\u2013S34 (2002).","journal-title":"Eur. J. Pediatr."},{"key":"1171_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/BF02239550","volume":"11","author":"K Hamaoka","year":"1990","unstructured":"Hamaoka, K., Nakagawa, M., Furukawa, N. & Sawada, T. Pulmonary hypertension in type I glycogen storage disease. Pediatr. Cardiol. 11, 54\u201356 (1990).","journal-title":"Pediatr. Cardiol."},{"key":"1171_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1183\/09031936.02.00258702","volume":"20","author":"M Humbert","year":"2002","unstructured":"Humbert, M. et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. Eur. Respir. J. 20, 59\u201365 (2002).","journal-title":"Eur. Respir. J."},{"key":"1171_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1542\/peds.65.2.341","volume":"65","author":"CJ Pizzo","year":"1980","unstructured":"Pizzo, C. J. Type I glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension. Pediatrics 65, 341\u2013343 (1980).","journal-title":"Pediatrics"},{"key":"1171_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/BF01799337","volume":"13","author":"N Furukawa","year":"1990","unstructured":"Furukawa, N. et al. Type I glycogen storage disease with vasoconstrictive pulmonary hypertension. J. Inherit. Metab. Dis. 13, 102\u2013107 (1990).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF00710433","volume":"18","author":"T Ohura","year":"1995","unstructured":"Ohura, T. et al. Progressive pulmonary hypertension: a fatal complication of type I glycogen storage disease. J. Inherit. Metab. Dis. 18, 361\u2013362 (1995).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF02524807","volume":"17","author":"D Bolz","year":"1996","unstructured":"Bolz, D., Stocker, F. & Zimmermann, A. Pulmonary vascular disease in a child with atrial septal defect of the secundum type and type I glycogen storage disease. Pediatr. Cardiol. 17, 265\u2013267 (1996).","journal-title":"Pediatr. Cardiol."},{"key":"1171_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF01799432","volume":"19","author":"P Kishnani","year":"1996","unstructured":"Kishnani, P., Bengur, A. R. & Chen, Y. T. Pulmonary hypertension in glycogen storage disease type I. J. Inherit. Metab. Dis. 19, 213\u2013216 (1996).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1321-0","volume":"15","author":"YM Kim","year":"2020","unstructured":"Kim, Y. M. et al. Predominance of the c.648G>T G6PC gene mutation and late complications in Korean patients with glycogen storage disease type Ia. Orphanet J. Rare Dis. 15, 45 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"1171_CR23","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1253\/circj.CJ-08-0181","volume":"73","author":"M Ueno","year":"2009","unstructured":"Ueno, M., Murakami, T., Takeda, A. & Kubota, M. Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease. Circ. J. 73, 1965\u20131968 (2009).","journal-title":"Circ. J."},{"key":"1171_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/2326409817707773","volume":"5","author":"RD Torok","year":"2017","unstructured":"Torok, R. D. et al. Pulmonary arterial hypertension in glycogen storage disease type I. J. Inborn Errors Metab. Screen. 5, 2326409817707773 (2017).","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"1171_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/bjh.12740","volume":"165","author":"B Tavil","year":"2014","unstructured":"Tavil, B., Cetin, M. & Gumruk, F. Sea-blue histiocytes in the bone marrow of a boy with severe congenital neutropenia associated with G6PC3 mutation. Br. J. Haematol. 165, 426 (2014).","journal-title":"Br. J. Haematol."},{"key":"1171_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.70014","volume":"48","author":"DA Weinstein","year":"2025","unstructured":"Weinstein, D. A. et al. Safety and efficacy of DTX401, an AAV8-mediated liver-directed gene therapy, in adults with glycogen storage disease type I a (GSDIa). J. Inherit. Metab. Dis. 48, e70014 (2025).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1310317","volume":"12","author":"AD Dornelles","year":"2024","unstructured":"Dornelles, A. D. et al. Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis. Front. Pediatr. 12, 1310317 (2024).","journal-title":"Front. Pediatr."},{"key":"1171_CR28","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00246-008-9267-3","volume":"29","author":"JC Levine","year":"2008","unstructured":"Levine, J. C., Kishnani, P. S., Chen, Y. T., Herlong, J. R. & Li, J. S. Cardiac remodeling after enzyme replacement therapy with acid \u03b1-glucosidase for infants with Pompe disease. Pediatr. Cardiol. 29, 1033\u20131042 (2008).","journal-title":"Pediatr. Cardiol."},{"key":"1171_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ymgme.2007.07.009","volume":"92","author":"TM Geel","year":"2007","unstructured":"Geel, T. M., McLaughlin, P. M., de Leij, L. F., Ruiters, M. H. & Niezen-Koning, K. E. Pompe disease: current state of treatment modalities and animal models. Mol. Genet. Metab. 92, 299\u2013307 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"1171_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1360369","volume":"15","author":"AK Desai","year":"2024","unstructured":"Desai, A. K. et al. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation. Front. Immunol. 15, 1360369 (2024).","journal-title":"Front. Immunol."},{"key":"1171_CR31","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/humu.23878","volume":"40","author":"AJJ Reuser","year":"2019","unstructured":"Reuser, A. J. J. et al. GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry. Hum. Mutat. 40, 2146\u20132164 (2019).","journal-title":"Hum. Mutat."},{"key":"1171_CR32","doi-asserted-by":"publisher","first-page":"1221140","DOI":"10.3389\/fped.2023.1221140","volume":"11","author":"R Colburn","year":"2023","unstructured":"Colburn, R. & Lapidus, D. An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion. Front. Pediatr. 11, 1221140 (2023).","journal-title":"Front. Pediatr."},{"key":"1171_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1957","volume":"10","author":"M Ceron-Rodriguez","year":"2022","unstructured":"Ceron-Rodriguez, M. et al. Classic infantile-onset Pompe disease with histopathological neurologic findings linked to a novel GAA gene 4 bp deletion: a case study. Mol. Genet. Genom. Med. 10, e1957 (2022).","journal-title":"Mol. Genet. Genom. Med."},{"key":"1171_CR34","doi-asserted-by":"publisher","first-page":"S333","DOI":"10.1007\/s10545-010-9179-2","volume":"33","author":"MA Hamdan","year":"2010","unstructured":"Hamdan, M. A., El-Zoabi, B. A., Begam, M. A., Mirghani, H. M. & Almalik, M. H. Antenatal diagnosis of Pompe disease by fetal echocardiography: impact on outcome after early initiation of enzyme replacement therapy. J. Inherit. Metab. Dis. 33, S333\u2013S339 (2010).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR35","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMoa2200587","volume":"387","author":"JL Cohen","year":"2022","unstructured":"Cohen, J. L. et al. In utero enzyme-replacement therapy for infantile-onset Pompe\u2019s disease. N. Engl. J. Med. 387, 2150\u20132158 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1171_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65259-8","volume":"10","author":"JY Saccconi","year":"2020","unstructured":"Saccconi, J. Y. et al. CRISPR-Cas9 generated Pompe knock-in murine model exhibits early-onset hypertrophic cardiomyopathy and skeletal muscle weakness. Sci. Rep. 10, 10321 (2020).","journal-title":"Sci. Rep."},{"key":"1171_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233050","volume":"15","author":"MP Belfiore","year":"2020","unstructured":"Belfiore, M. P. et al. Aortopathies in mouse models of Pompe, Fabry and mucopolysaccharidosis IIIB lysosomal storage diseases. PLoS ONE 15, e0233050 (2020).","journal-title":"PLoS ONE"},{"key":"1171_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13573","volume":"57","author":"W Huang","year":"2024","unstructured":"Huang, W. et al. Mitochondrial dysfunction is associated with hypertrophic cardiomyopathy in Pompe disease-specific induced pluripotent stem cell-derived cardiomyocytes. Cell Prolif. 57, e13573 (2024).","journal-title":"Cell Prolif."},{"key":"1171_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","volume":"11","author":"JA Lim","year":"2015","unstructured":"Lim, J. A., Li, L., Kakhlon, O., Myerowitz, R. & Raben, N. Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy 11, 385\u2013402 (2015).","journal-title":"Autophagy"},{"key":"1171_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HM van den Hout","year":"2003","unstructured":"van den Hout, H. M. et al. The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112, 332\u2013340 (2003).","journal-title":"Pediatrics"},{"key":"1171_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF02265613","volume":"2","author":"S Bharati","year":"1982","unstructured":"Bharati, S. et al. The conduction system in Pompe\u2019s disease. Pediatr. Cardiol. 2, 25\u201332 (1982).","journal-title":"Pediatr. Cardiol."},{"key":"1171_CR42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/brain\/awh384","volume":"128","author":"ML Hagemans","year":"2005","unstructured":"Hagemans, M. L. et al. Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients. Brain 128, 671\u2013677 (2005).","journal-title":"Brain"},{"key":"1171_CR43","first-page":"79","volume":"31","author":"M Mori","year":"2017","unstructured":"Mori, M. et al. Severe cardiomyopathy as the isolated presenting feature in an adult with late-onset Pompe disease: a case report. JIMD Rep. 31, 79\u201383 (2017).","journal-title":"JIMD Rep."},{"key":"1171_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2796.2008.01966.x","volume":"264","author":"OI Soliman","year":"2008","unstructured":"Soliman, O. I. et al. Cardiac involvement in adults with Pompe disease. J. Intern. Med. 264, 333\u2013339 (2008).","journal-title":"J. Intern. Med."},{"key":"1171_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12968-016-0311-9","volume":"18","author":"M Boentert","year":"2016","unstructured":"Boentert, M., Florian, A., Drager, B., Young, P. & Yilmaz, A. Pattern and prognostic value of cardiac involvement in patients with late-onset Pompe disease: a comprehensive cardiovascular magnetic resonance approach. J. Cardiovasc. Magn. Reson. 18, 91 (2016).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"1171_CR46","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.nmd.2014.04.005","volume":"24","author":"S Sacconi","year":"2014","unstructured":"Sacconi, S. et al. Atrio-ventricular block requiring pacemaker in patients with late onset Pompe disease. Neuromuscul. Disord. 24, 648\u2013650 (2014).","journal-title":"Neuromuscul. Disord."},{"key":"1171_CR47","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10554-015-0629-7","volume":"31","author":"DA Morris","year":"2015","unstructured":"Morris, D. A. et al. Structural and functional cardiac analyses using modern and sensitive myocardial techniques in adult Pompe disease. Int. J. Cardiovasc. Imaging 31, 947\u2013956 (2015).","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"1171_CR48","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10877-014-9551-0","volume":"28","author":"A Fayssoil","year":"2014","unstructured":"Fayssoil, A., Nardi, O., Annane, D. & Orlikowski, D. Right ventricular function in late-onset Pompe disease. J. Clin. Monit. Comput. 28, 419\u2013421 (2014).","journal-title":"J. Clin. Monit. Comput."},{"key":"1171_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.nmd.2020.10.009","volume":"31","author":"HA van Kooten","year":"2021","unstructured":"van Kooten, H. A. et al. Cardiovascular disease in non-classic Pompe disease: a systematic review. Neuromuscul. Disord. 31, 79\u201390 (2021).","journal-title":"Neuromuscul. Disord."},{"key":"1171_CR50","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ymgme.2012.05.007","volume":"106","author":"LD Hobson-Webb","year":"2012","unstructured":"Hobson-Webb, L. D. et al. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol. Genet. Metab. 106, 462\u2013469 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"1171_CR51","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/mus.880100311","volume":"10","author":"JD van der Walt","year":"1987","unstructured":"van der Walt, J. D., Swash, M., Leake, J. & Cox, E. L. The pattern of involvement of adult-onset acid maltase deficiency at autopsy. Muscle Nerve 10, 272\u2013281 (1987).","journal-title":"Muscle Nerve"},{"key":"1171_CR52","first-page":"27","volume":"20","author":"O Hensel","year":"2015","unstructured":"Hensel, O. et al. Morphology and function of cerebral arteries in adults with pompe disease. JIMD Rep. 20, 27\u201333 (2015).","journal-title":"JIMD Rep."},{"key":"1171_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/ejcts\/ezs489","volume":"43","author":"V Goeber","year":"2013","unstructured":"Goeber, V., Banz, Y., Kaeberich, A. & Carrel, T. Huge aneurysm of the ascending aorta in a patient with adult-type Pompe\u2019s disease: histological findings mimicking fibrillinopathy. Eur. J. Cardiothorac. Surg. 43, 193\u2013195 (2013).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"1171_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ymgme.2011.04.009","volume":"103","author":"AH El-Gharbawy","year":"2011","unstructured":"El-Gharbawy, A. H. et al. Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered. Mol. Genet. Metab. 103, 362\u2013366 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"1171_CR55","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4103\/0366-6999.232792","volume":"131","author":"HP Li","year":"2018","unstructured":"Li, H. P. et al. Pulmonary hypertension in glycogen storage disease type II. Chin. Med. J. 131, 1375\u20131376 (2018).","journal-title":"Chin. Med. J."},{"key":"1171_CR56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ymgme.2010.01.015","volume":"100","author":"H Kobayashi","year":"2010","unstructured":"Kobayashi, H. et al. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol. Genet. Metab. 100, 14\u201319 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"1171_CR57","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.4187\/respcare.03419","volume":"60","author":"CF Yang","year":"2015","unstructured":"Yang, C. F. et al. Late-onset Pompe disease with left-sided bronchomalacia. Respir. Care 60, e26\u2013e29 (2015).","journal-title":"Respir. Care"},{"key":"1171_CR58","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"PS Kishnani","year":"2006","unstructured":"Kishnani, P. S. et al. Pompe disease diagnosis and management guideline. Genet. Med. 8, 267\u2013288 (2006).","journal-title":"Genet. Med."},{"key":"1171_CR59","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1017\/cjn.2016.37","volume":"43","author":"M Tarnopolsky","year":"2016","unstructured":"Tarnopolsky, M. et al. Pompe disease: diagnosis and management. Evidence-based guidelines from a Canadian expert panel. Can. J. Neurol. Sci. 43, 472\u2013485 (2016).","journal-title":"Can. J. Neurol. Sci."},{"key":"1171_CR60","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg, A. T. et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur. J. Neurol. 24, 768\u2013e31 (2017).","journal-title":"Eur. J. Neurol."},{"key":"1171_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03373-w","volume":"19","author":"G Parenti","year":"2024","unstructured":"Parenti, G. et al. The European Reference Network for Metabolic Diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II). Orphanet J. Rare Dis. 19, 408 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"1171_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16383","volume":"31","author":"B Schoser","year":"2024","unstructured":"Schoser, B. et al. Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. Eur. J. Neurol. 31, e16383 (2024).","journal-title":"Eur. J. Neurol."},{"key":"1171_CR63","doi-asserted-by":"publisher","first-page":"9798","DOI":"10.4081\/ejtm.2021.9798","volume":"31","author":"C Angelini","year":"2021","unstructured":"Angelini, C. Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC consortium. Eur. J. Transl. Myol. 31, 9798 (2021).","journal-title":"Eur. J. Transl. Myol."},{"key":"1171_CR64","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo, E. et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur. Heart J. 44, 3503\u20133626 (2023).","journal-title":"Eur. Heart J."},{"key":"1171_CR65","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser, B. et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 20, 1027\u20131037 (2021).","journal-title":"Lancet Neurol."},{"key":"1171_CR66","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3390\/ph16091199","volume":"16","author":"L Fiege","year":"2023","unstructured":"Fiege, L., Duran, I. & Marquardt, T. Improved enzyme replacement therapy with cipaglucosidase alfa\/miglustat in infantile Pompe disease. Pharmaceuticals 16, 1199 (2023).","journal-title":"Pharmaceuticals"},{"key":"1171_CR67","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40265-023-01886-5","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair, H. A. Cipaglucosidase alfa: first approval. Drugs 83, 739\u2013745 (2023).","journal-title":"Drugs"},{"key":"1171_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.10.010","volume":"25","author":"PS Kishnani","year":"2023","unstructured":"Kishnani, P. S. et al. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report. Genet. Med. 25, 100328 (2023).","journal-title":"Genet. Med."},{"key":"1171_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.903488","volume":"13","author":"D Zhu","year":"2022","unstructured":"Zhu, D. et al. A multi-centre prospective study of the efficacy and safety of alglucosidase alfa in Chinese patients with infantile-onset Pompe disease. Front. Pharmacol. 13, 903488 (2022).","journal-title":"Front. Pharmacol."},{"key":"1171_CR70","volume":"40","author":"T Mozaffar","year":"2024","unstructured":"Mozaffar, T. et al. Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naive patients with late-onset Pompe disease: a pooled analysis of clinical trials. Mol. Genet. Metab. Rep. 40, 101109 (2024).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1171_CR71","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","volume":"99","author":"MM Dimachkie","year":"2022","unstructured":"Dimachkie, M. M. et al. Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease. Neurology 99, e536\u2013e548 (2022).","journal-title":"Neurology"},{"key":"1171_CR72","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125358","volume":"4","author":"S Xu","year":"2019","unstructured":"Xu, S. et al. Improved efficacy of a next-generation ERT in murine Pompe disease. JCI Insight 4, e125358 (2019).","journal-title":"JCI Insight"},{"key":"1171_CR73","first-page":"101085","volume":"39","author":"B Schoser","year":"2024","unstructured":"Schoser, B., Raben, N., Varfaj, F., Walzer, M. & Toscano, A. Acid \u03b1-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: a systematic review. Mol. Genet. Metab. Rep. 39, 101085 (2024).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1171_CR74","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/GIM.0b013e318183722f","volume":"10","author":"R McDowell","year":"2008","unstructured":"McDowell, R. et al. Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease. Genet. Med. 10, 758\u2013762 (2008).","journal-title":"Genet. Med."},{"key":"1171_CR75","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","volume":"117","author":"PS Kishnani","year":"2016","unstructured":"Kishnani, P. S. et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol. Genet. Metab. 117, 66\u201383 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"1171_CR76","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani, P. S. et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. 99, 26\u201333 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"1171_CR77","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3389\/fimmu.2020.01727","volume":"11","author":"AK Desai","year":"2020","unstructured":"Desai, A. K., Baloh, C. H., Sleasman, J. W., Rosenberg, A. S. & Kishnani, P. S. Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: demonstration of long-term safety and efficacy in an expanded cohort. Front. Immunol. 11, 1727 (2020).","journal-title":"Front. Immunol."},{"key":"1171_CR78","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94328","volume":"2","author":"ZB Kazi","year":"2017","unstructured":"Kazi, Z. B. et al. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight 2, e94328 (2017).","journal-title":"JCI Insight"},{"key":"1171_CR79","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","volume":"23","author":"C Li","year":"2021","unstructured":"Li, C. et al. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet. Med. 23, 845\u2013855 (2021).","journal-title":"Genet. Med."},{"key":"1171_CR80","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/gim.2012.110","volume":"15","author":"SG Banugaria","year":"2013","unstructured":"Banugaria, S. G. et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet. Med. 15, 123\u2013131 (2013).","journal-title":"Genet. Med."},{"key":"1171_CR81","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1093\/hmg\/ddn290","volume":"17","author":"G Douillard-Guilloux","year":"2008","unstructured":"Douillard-Guilloux, G. et al. Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Hum. Mol. Genet. 17, 3876\u20133886 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"1171_CR82","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/hmg\/ddp535","volume":"19","author":"G Douillard-Guilloux","year":"2010","unstructured":"Douillard-Guilloux, G. et al. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum. Mol. Genet. 19, 684\u2013696 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"1171_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.57","volume":"3","author":"NP Clayton","year":"2014","unstructured":"Clayton, N. P. et al. Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease. Mol. Ther. Nucleic Acids 3, e206 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1171_CR84","doi-asserted-by":"publisher","first-page":"eadf1691","DOI":"10.1126\/scitranslmed.adf1691","volume":"16","author":"JC Ullman","year":"2024","unstructured":"Ullman, J. C. et al. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders. Sci. Transl. Med. 16, eadf1691 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1171_CR85","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/cpt.3470","volume":"116","author":"JC Ullman","year":"2024","unstructured":"Ullman, J. C. et al. First-in-human evaluation of safety, pharmacokinetics and muscle glycogen lowering of a novel glycogen synthase 1 inhibitor for the treatment of Pompe disease. Clin. Pharmacol. Ther. 116, 1580\u20131592 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1171_CR86","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/biomedicines10020302","volume":"10","author":"Z Unnisa","year":"2022","unstructured":"Unnisa, Z., Yoon, J. K., Schindler, J. W., Mason, C. & van Til, N. P. Gene therapy developments for Pompe disease. Biomedicines 10, 302 (2022).","journal-title":"Biomedicines"},{"key":"1171_CR87","first-page":"263300402210764","volume":"3","author":"C Bordoli","year":"2022","unstructured":"Bordoli, C., Murphy, E., Varley, I., Sharpe, G. & Hennis, P. A systematic review investigating the effectiveness of exercise training in glycogen storage diseases. Ther. Adv. Rare Dis. 3, 26330040221076497 (2022).","journal-title":"Ther. Adv. Rare Dis."},{"key":"1171_CR88","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.jacc.2018.08.2141","volume":"72","author":"GF Fletcher","year":"2018","unstructured":"Fletcher, G. F. et al. Promoting physical activity and exercise: JACC Health Promotion Series. J. Am. Coll. Cardiol. 72, 1622\u20131639 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1171_CR89","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/CIRCRESAHA.118.312669","volume":"124","author":"CJ Lavie","year":"2019","unstructured":"Lavie, C. J., Ozemek, C., Carbone, S., Katzmarzyk, P. T. & Blair, S. N. Sedentary behavior, exercise, and cardiovascular health. Circ. Res. 124, 799\u2013815 (2019).","journal-title":"Circ. Res."},{"key":"1171_CR90","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMoa011858","volume":"346","author":"J Myers","year":"2002","unstructured":"Myers, J. et al. Exercise capacity and mortality among men referred for exercise testing. N. Engl. J. Med. 346, 793\u2013801 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1171_CR91","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCULATIONAHA.107.734764","volume":"117","author":"P Kokkinos","year":"2008","unstructured":"Kokkinos, P. et al. Exercise capacity and mortality in black and white men. Circulation 117, 614\u2013622 (2008).","journal-title":"Circulation"},{"key":"1171_CR92","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/j.jacc.2003.07.028","volume":"42","author":"T Kavanagh","year":"2003","unstructured":"Kavanagh, T. et al. Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. J. Am. Coll. Cardiol. 42, 2139\u20132143 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1171_CR93","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1161\/CIR.0000000000000461","volume":"134","author":"R Ross","year":"2016","unstructured":"Ross, R. et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a Scientific Statement from the American Heart Association. Circulation 134, e653\u2013e699 (2016).","journal-title":"Circulation"},{"key":"1171_CR94","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231224233","volume":"15","author":"A Evins","year":"2024","unstructured":"Evins, A. et al. Glycogen storage disease type III: a mixed-methods study to assess the burden of disease. Ther. Adv. Endocrinol. Metab. 15, 20420188231224233 (2024).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"1171_CR95","volume":"29","author":"G Hijazi","year":"2021","unstructured":"Hijazi, G. et al. A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III. Mol. Genet. Metab. Rep. 29, 100821 (2021).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1171_CR96","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/jimd.12355","volume":"44","author":"E Berling","year":"2021","unstructured":"Berling, E. et al. Narrative review of glycogen storage disorder type III with a focus on neuromuscular, cardiac and therapeutic aspects. J. Inherit. Metab. Dis. 44, 521\u2013533 (2021).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR97","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10545-016-9932-2","volume":"39","author":"CP Sentner","year":"2016","unstructured":"Sentner, C. P. et al. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. J. Inherit. Metab. Dis. 39, 697\u2013704 (2016).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR98","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/GIM.0b013e3181e0e979","volume":"12","author":"SM Vertilus","year":"2010","unstructured":"Vertilus, S. M. et al. Echocardiographic manifestations of glycogen storage disease III: increase in wall thickness and left ventricular mass over time. Genet. Med. 12, 413\u2013423 (2010).","journal-title":"Genet. Med."},{"key":"1171_CR99","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00431-015-2546-0","volume":"174","author":"EA Mogahed","year":"2015","unstructured":"Mogahed, E. A. et al. Skeletal and cardiac muscle involvement in children with glycogen storage disease type III. Eur. J. Pediatr. 174, 1545\u20131548 (2015).","journal-title":"Eur. J. Pediatr."},{"key":"1171_CR100","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/BF01744800","volume":"8","author":"JS Carvalho","year":"1993","unstructured":"Carvalho, J. S., Matthews, E. E., Leonard, J. V. & Deanfield, J. Cardiomyopathy of glycogen storage disease type III. Heart Vessels 8, 155\u2013159 (1993).","journal-title":"Heart Vessels"},{"key":"1171_CR101","first-page":"65","volume":"6","author":"SL Austin","year":"2012","unstructured":"Austin, S. L. et al. Cardiac pathology in glycogen storage disease type III. JIMD Rep. 6, 65\u201372 (2012).","journal-title":"JIMD Rep."},{"key":"1171_CR102","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/0002-8703(95)90097-7","volume":"130","author":"H Tada","year":"1995","unstructured":"Tada, H. et al. Glycogen storage disease type III associated with ventricular tachycardia. Am. Heart J. 130, 911\u2013912 (1995).","journal-title":"Am. Heart J."},{"key":"1171_CR103","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/(SICI)1098-1004(1997)9:1<37::AID-HUMU6>3.0.CO;2-M","volume":"9","author":"J Shen","year":"1997","unstructured":"Shen, J., Bao, Y. & Chen, Y. T. A nonsense mutation due to a single base insertion in the 3\u2032-coding region of glycogen debranching enzyme gene associated with a severe phenotype in a patient with glycogen storage disease type IIIa. Hum. Mutat. 9, 37\u201340 (1997).","journal-title":"Hum. Mutat."},{"key":"1171_CR104","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/hrt.34.8.862","volume":"34","author":"CG Miller","year":"1972","unstructured":"Miller, C. G., Alleyne, G. A. & Brooks, S. E. Gross cardiac involvement in glycogen storage disease type 3. Br. Heart J. 34, 862\u2013864 (1972).","journal-title":"Br. Heart J."},{"key":"1171_CR105","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/oxfordjournals.eurheartj.a015283","volume":"18","author":"H Akazawa","year":"1997","unstructured":"Akazawa, H. et al. Specific heart muscle disease associated with glycogen storage disease type III: clinical similarity to the dilated phase of hypertrophic cardiomyopathy. Eur. Heart J. 18, 532\u2013533 (1997).","journal-title":"Eur. Heart J."},{"key":"1171_CR106","first-page":"79","volume":"1","author":"TM Lee","year":"2011","unstructured":"Lee, T. M., Berman-Rosenzweig, E. S., Slonim, A. E. & Chung, W. K. Two cases of pulmonary hypertension associated with type III glycogen storage disease. JIMD Rep. 1, 79\u201382 (2011).","journal-title":"JIMD Rep."},{"key":"1171_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01212-5","volume":"28","author":"C Wicker","year":"2023","unstructured":"Wicker, C. et al. French recommendations for the management of glycogen storage disease type III. Eur. J. Med. Res. 28, 253 (2023).","journal-title":"Eur. J. Med. Res."},{"key":"1171_CR108","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/GIM.0b013e3181e655b6","volume":"12","author":"PS Kishnani","year":"2010","unstructured":"Kishnani, P. S. et al. Glycogen storage disease type III diagnosis and management guidelines. Genet. Med. 12, 446\u2013463 (2010).","journal-title":"Genet. Med."},{"key":"1171_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0196-3","volume":"9","author":"S Mayorandan","year":"2014","unstructured":"Mayorandan, S., Meyer, U., Hartmann, H. & Das, A. M. Glycogen storage disease type III: modified Atkins diet improves myopathy. Orphanet J. Rare Dis. 9, 196 (2014).","journal-title":"Orphanet J. Rare Dis."},{"key":"1171_CR110","first-page":"100904","volume":"32","author":"B Kumru Akin","year":"2022","unstructured":"Kumru Akin, B., Ozturk Hismi, B. & Daly, A. Improvement in hypertrophic cardiomyopathy after using a high-fat, high-protein and low-carbohydrate diet in a non-adherent child with glycogen storage disease type IIIa. Mol. Genet. Metab. Rep. 32, 100904 (2022).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1171_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2020.106205","volume":"32","author":"T Marusic","year":"2020","unstructured":"Marusic, T. et al. Data highlighting effects of ketogenic diet on cardiomyopathy and hepatopathy in glycogen storage disease type IIIA. Data Brief. 32, 106205 (2020).","journal-title":"Data Brief."},{"key":"1171_CR112","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1007\/s10545-009-1088-x","volume":"32","author":"AI Dagli","year":"2009","unstructured":"Dagli, A. I. et al. Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. J. Inherit. Metab. Dis. 32, S103\u2013S106 (2009).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR113","volume":"24","author":"T Marusic","year":"2020","unstructured":"Marusic, T. et al. Normalization of obstructive cardiomyopathy and improvement of hepatopathy on ketogenic diet in patient with glycogen storage disease (GSD) type IIIa. Mol. Genet. Metab. Rep. 24, 100628 (2020).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1171_CR114","first-page":"91","volume":"17","author":"A Brambilla","year":"2014","unstructured":"Brambilla, A. et al. Improvement of cardiomyopathy after high-fat diet in two siblings with glycogen storage disease type III. JIMD Rep. 17, 91\u201395 (2014).","journal-title":"JIMD Rep."},{"key":"1171_CR115","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1203\/PDR.0b013e318232154f","volume":"70","author":"V Valayannopoulos","year":"2011","unstructured":"Valayannopoulos, V. et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III with D,L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr. Res. 70, 638\u2013641 (2011).","journal-title":"Pediatr. Res."},{"key":"1171_CR116","first-page":"17","volume":"38","author":"F Francini-Pesenti","year":"2019","unstructured":"Francini-Pesenti, F., Tresso, S. & Vitturi, N. Modified Atkins ketogenic diet improves heart and skeletal muscle function in glycogen storage disease type III. Acta Myol. 38, 17\u201320 (2019).","journal-title":"Acta Myol."},{"key":"1171_CR117","first-page":"13","volume":"5","author":"CP Sentner","year":"2012","unstructured":"Sentner, C. P., Caliskan, K., Vletter, W. B. & Smit, G. P. Heart failure due to severe hypertrophic cardiomyopathy reversed by low calorie, high protein dietary adjustments in a glycogen storage disease type IIIa patient. JIMD Rep. 5, 13\u201316 (2012).","journal-title":"JIMD Rep."},{"key":"1171_CR118","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.omtm.2020.05.034","volume":"18","author":"JA Lim","year":"2020","unstructured":"Lim, J. A., Choi, S. J., Gao, F., Kishnani, P. S. & Sun, B. A novel gene therapy approach for GSD III using an AAV vector encoding a bacterial glycogen debranching enzyme. Mol. Ther. Methods Clin. Dev. 18, 240\u2013249 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1171_CR119","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172018","volume":"134","author":"A Gardin","year":"2024","unstructured":"Gardin, A. et al. A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III. J. Clin. Invest. 134, e172018 (2024).","journal-title":"J. Clin. Invest."},{"key":"1171_CR120","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00109-014-1127-4","volume":"92","author":"H Yi","year":"2014","unstructured":"Yi, H. et al. Correction of glycogen storage disease type III with rapamycin in a canine model. J. Mol. Med. 92, 641\u2013650 (2014).","journal-title":"J. Mol. Med."},{"key":"1171_CR121","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.ymthe.2018.04.023","volume":"26","author":"N Pursell","year":"2018","unstructured":"Pursell, N. et al. Inhibition of glycogen synthase II with RNAi prevents liver injury in mouse models of glycogen storage diseases. Mol. Ther. 26, 1771\u20131782 (2018).","journal-title":"Mol. Ther."},{"key":"1171_CR122","unstructured":"Magoulas, P. L. & El-Hattab, A. W. Glycogen Storage Disease Type IV (eds Adam, M. P. et al.) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK115333\/ (GeneReviews, 2019)."},{"key":"1171_CR123","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/biomedicines11020363","volume":"11","author":"M Wilke","year":"2023","unstructured":"Wilke, M. et al. A broad characterization of glycogen storage disease IV patients: a clinical, genetic, and histopathological study. Biomedicines 11, 363 (2023).","journal-title":"Biomedicines"},{"key":"1171_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.992406","volume":"13","author":"BT Kiely","year":"2022","unstructured":"Kiely, B. T. et al. A novel approach to characterize phenotypic variation in GSD IV: reconceptualizing the clinical continuum. Front. Genet. 13, 992406 (2022).","journal-title":"Front. Genet."},{"key":"1171_CR125","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/hmg\/ddq492","volume":"20","author":"YC Lee","year":"2011","unstructured":"Lee, Y. C., Chang, C. J., Bali, D., Chen, Y. T. & Yan, Y. T. Glycogen-branching enzyme deficiency leads to abnormal cardiac development: novel insights into glycogen storage disease IV. Hum. Mol. Genet. 20, 455\u2013465 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"1171_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-230068","volume":"12","author":"MK Ndugga-Kabuye","year":"2019","unstructured":"Ndugga-Kabuye, M. K., Maleszewski, J., Chanprasert, S. & Smith, K. D. Glycogen storage disease type IV: dilated cardiomyopathy as the isolated initial presentation in an adult patient. BMJ Case Rep. 12, e230068 (2019).","journal-title":"BMJ Case Rep."},{"key":"1171_CR127","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/ana.23598","volume":"72","author":"F Mochel","year":"2012","unstructured":"Mochel, F. et al. Adult polyglucosan body disease: natural history and key magnetic resonance imaging findings. Ann. Neurol. 72, 433\u2013441 (2012).","journal-title":"Ann. Neurol."},{"key":"1171_CR128","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/oxfordjournals.eurheartj.a060797","volume":"16","author":"S Nase","year":"1995","unstructured":"Nase, S. et al. A new variant of type IV glycogenosis with primary cardiac manifestation and complete branching enzyme deficiency. In vivo detection by heart muscle biopsy. Eur. Heart J. 16, 1698\u20131704 (1995).","journal-title":"Eur. Heart J."},{"key":"1171_CR129","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/BF00334454","volume":"85","author":"JM Schroder","year":"1993","unstructured":"Schroder, J. M., May, R., Shin, Y. S., Sigmund, M. & Nase-Huppmeier, S. Juvenile hereditary polyglucosan body disease with complete branching enzyme deficiency (type IV glycogenosis). Acta Neuropathol. 85, 419\u2013430 (1993).","journal-title":"Acta Neuropathol."},{"key":"1171_CR130","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1172\/JCI118517","volume":"97","author":"Y Bao","year":"1996","unstructured":"Bao, Y., Kishnani, P., Wu, J. Y. & Chen, Y. T. Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. J. Clin. Invest. 97, 941\u2013948 (1996).","journal-title":"J. Clin. Invest."},{"key":"1171_CR131","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/BF00294181","volume":"87","author":"TT Tang","year":"1994","unstructured":"Tang, T. T. et al. Neonatal hypotonia and cardiomyopathy secondary to type IV glycogenosis. Acta Neuropathol. 87, 531\u2013536 (1994).","journal-title":"Acta Neuropathol."},{"key":"1171_CR132","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0022-3476(87)80341-4","volume":"111","author":"S Servidei","year":"1987","unstructured":"Servidei, S. et al. Severe cardiopathy in branching enzyme deficiency. J. Pediatr. 111, 51\u201356 (1987).","journal-title":"J. Pediatr."},{"key":"1171_CR133","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1007\/s10545-008-0819-8","volume":"31","author":"TF Eminoglu","year":"2008","unstructured":"Eminoglu, T. F. et al. Multisystem involvement in a patient due to accumulation of amylopectin-like material with diminished branching enzyme activity. J. Inherit. Metab. Dis. 31, S255\u2013S259 (2008).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR134","doi-asserted-by":"publisher","first-page":"764286","DOI":"10.1155\/2012\/764286","volume":"2012","author":"T Aksu","year":"2012","unstructured":"Aksu, T., Colak, A. & Tufekcioglu, O. Cardiac involvement in glycogen storage disease type IV: two cases and the two ends of a spectrum. Case Rep. Med. 2012, 764286 (2012).","journal-title":"Case Rep. Med."},{"key":"1171_CR135","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5114\/aoms.2018.72246","volume":"14","author":"E Szymanska","year":"2018","unstructured":"Szymanska, E. et al. Variable clinical presentation of glycogen storage disease type IV: from severe hepatosplenomegaly to cardiac insufficiency. Some discrepancies in genetic and biochemical abnormalities. Arch. Med. Sci. 14, 237\u2013247 (2018).","journal-title":"Arch. Med. Sci."},{"key":"1171_CR136","doi-asserted-by":"publisher","first-page":"C130","DOI":"10.1093\/eurheartjsupp\/suad015","volume":"25","author":"GD Aquaro","year":"2023","unstructured":"Aquaro, G. D. et al. Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies. Eur. Heart J. Suppl. 25, C130\u2013C136 (2023).","journal-title":"Eur. Heart J. Suppl."},{"key":"1171_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa078","volume":"4","author":"S Lyo","year":"2020","unstructured":"Lyo, S., Miles, J., Meisner, J. & Guelfguat, M. Case report: adult-onset manifesting heterozygous glycogen storage disease type IV with dilated cardiomyopathy and absent late gadolinium enhancement on cardiac magnetic resonance imaging. Eur. Heart J. Case Rep. 4, 1\u20136 (2020).","journal-title":"Eur. Heart J. Case Rep."},{"key":"1171_CR138","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/BF01954384","volume":"151","author":"EM Sokal","year":"1992","unstructured":"Sokal, E. M. et al. Progressive cardiac failure following orthotopic liver transplantation for type IV glycogenosis. Eur. J. Pediatr. 151, 200\u2013203 (1992).","journal-title":"Eur. J. Pediatr."},{"key":"1171_CR139","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/MPG.0b013e3181d29780","volume":"51","author":"S Willot","year":"2010","unstructured":"Willot, S., Marchand, V., Rasquin, A., Alvarez, F. & Martin, S. R. Systemic progression of type IV glycogen storage disease after liver transplantation. J. Pediatr. Gastroenterol. Nutr. 51, 661\u2013664 (2010).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"1171_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107525","volume":"138","author":"RL Koch","year":"2023","unstructured":"Koch, R. L. et al. Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: a clinical practice resource. Mol. Genet. Metab. 138, 107525 (2023).","journal-title":"Mol. Genet. Metab."},{"key":"1171_CR141","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1186\/s12864-017-4188-2","volume":"18","author":"A Santalla","year":"2017","unstructured":"Santalla, A. et al. Genotypic and phenotypic features of all Spanish patients with McArdle disease: a 2016 update. BMC Genom. 18, 819 (2017).","journal-title":"BMC Genom."},{"key":"1171_CR142","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/humu.22806","volume":"36","author":"G Nogales-Gadea","year":"2015","unstructured":"Nogales-Gadea, G. et al. McArdle disease: update of reported mutations and polymorphisms in the PYGM gene. Hum. Mutat. 36, 669\u2013678 (2015).","journal-title":"Hum. Mutat."},{"key":"1171_CR143","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.nmd.2021.10.006","volume":"31","author":"A Lucia","year":"2021","unstructured":"Lucia, A. et al. Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul. Disord. 31, 1296\u20131310 (2021).","journal-title":"Neuromuscul. Disord."},{"key":"1171_CR144","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1002\/ehf2.14060","volume":"9","author":"R Soria-Navarro","year":"2022","unstructured":"Soria-Navarro, R. et al. Cardiac arrest as a manifestation of unknown type V glycogenosis: a case report. Esc. Heart Fail. 9, 3625\u20133629 (2022).","journal-title":"Esc. Heart Fail."},{"key":"1171_CR145","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/jnnp-2011-301593","volume":"83","author":"A Lucia","year":"2012","unstructured":"Lucia, A. et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish National Registry. J. Neurol. Neurosurg. Psychiatry 83, 322\u2013328 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1171_CR146","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/ncpneuro0913","volume":"4","author":"A Lucia","year":"2008","unstructured":"Lucia, A. et al. McArdle disease: what do neurologists need to know? Nat. Clin. Pract. Neurol. 4, 568\u2013577 (2008).","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"1171_CR147","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1249\/MSS.0000000000003529","volume":"56","author":"A Santos-Lozano","year":"2024","unstructured":"Santos-Lozano, A. et al. Exercise intolerance in McArdle disease: a role for cardiac impairment? A preliminary study in humans and mice. Med. Sci. Sports Exerc. 56, 2241\u20132255 (2024).","journal-title":"Med. Sci. Sports Exerc."},{"key":"1171_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101648","volume":"66","author":"M Villarreal-Salazar","year":"2022","unstructured":"Villarreal-Salazar, M. et al. Low aerobic capacity in McArdle disease: a role for mitochondrial network impairment? Mol. Metab. 66, 101648 (2022).","journal-title":"Mol. Metab."},{"key":"1171_CR149","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/hrt.76.4.372","volume":"76","author":"DP Nicholls","year":"1996","unstructured":"Nicholls, D. P., Campbell, N. P., Stevenson, H. P. & Patterson, V. H. Angina in McArdle\u2019s disease. Heart 76, 372\u2013373 (1996).","journal-title":"Heart"},{"key":"1171_CR150","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1007\/s10072-024-07600-x","volume":"45","author":"D Hoxhaj","year":"2024","unstructured":"Hoxhaj, D. et al. Cardiac comorbidities in McArdle disease: case report and systematic review. Neurol. Sci. 45, 4757\u20134765 (2024).","journal-title":"Neurol. Sci."},{"key":"1171_CR151","doi-asserted-by":"publisher","first-page":"328","DOI":"10.7326\/0003-4819-62-2-328","volume":"62","author":"G Ratinov","year":"1965","unstructured":"Ratinov, G., Baker, W. P. & Swaiman, K. F. Mcardle\u2019s syndrome with previously unreported electrocardiographic and serum enzyme abnormalities. Ann. Intern. Med. 62, 328\u2013334 (1965).","journal-title":"Ann. Intern. Med."},{"key":"1171_CR152","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.hlc.2012.12.004","volume":"22","author":"S Moustafa","year":"2013","unstructured":"Moustafa, S., Patton, D. J. & Connelly, M. S. Unforeseen cardiac involvement in McArdle\u2019s disease. Heart Lung Circ. 22, 769\u2013771 (2013).","journal-title":"Heart Lung Circ."},{"key":"1171_CR153","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/eurheartj\/ehy783","volume":"40","author":"DM Jones","year":"2019","unstructured":"Jones, D. M., Lopes, L., Quinlivan, R., Elliott, P. M. & Khanji, M. Y. Cardiac manifestations of McArdle disease. Eur. Heart J. 40, 397\u2013398 (2019).","journal-title":"Eur. Heart J."},{"key":"1171_CR154","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/ana.10725","volume":"54","author":"J Vissing","year":"2003","unstructured":"Vissing, J. & Haller, R. G. A diagnostic cycle test for McArdle\u2019s disease. Ann. Neurol. 54, 539\u2013542 (2003).","journal-title":"Ann. Neurol."},{"key":"1171_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.744632","volume":"12","author":"E Salazar-Martinez","year":"2021","unstructured":"Salazar-Martinez, E. et al. The second wind in McArdle patients: fitness matters. Front. Physiol. 12, 744632 (2021).","journal-title":"Front. Physiol."},{"key":"1171_CR156","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jshs.2023.11.006","volume":"13","author":"PL Valenzuela","year":"2024","unstructured":"Valenzuela, P. L. et al. Dose-response effect of pre-exercise carbohydrates under muscle glycogen unavailability: insights from McArdle disease. J. Sport. Health Sci. 13, 398\u2013408 (2024).","journal-title":"J. Sport. Health Sci."},{"key":"1171_CR157","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1056\/NEJMoa031836","volume":"349","author":"J Vissing","year":"2003","unstructured":"Vissing, J. & Haller, R. G. The effect of oral sucrose on exercise tolerance in patients with McArdle\u2019s disease. N. Engl. J. Med. 349, 2503\u20132509 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1171_CR158","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/ana.20881","volume":"59","author":"RG Haller","year":"2006","unstructured":"Haller, R. G., Wyrick, P., Taivassalo, T. & Vissing, J. Aerobic conditioning: an effective therapy in McArdle\u2019s disease. Ann. Neurol. 59, 922\u2013928 (2006).","journal-title":"Ann. Neurol."},{"key":"1171_CR159","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1152\/japplphysiol.00885.2015","volume":"121","author":"S Porcelli","year":"2016","unstructured":"Porcelli, S., Marzorati, M., Morandi, L. & Grassi, B. Home-based aerobic exercise training improves skeletal muscle oxidative metabolism in patients with metabolic myopathies. J. Appl. Physiol. 121, 699\u2013708 (2016).","journal-title":"J. Appl. Physiol."},{"key":"1171_CR160","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/archneur.65.6.786","volume":"65","author":"ST Andersen","year":"2008","unstructured":"Andersen, S. T., Haller, R. G. & Vissing, J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch. Neurol. 65, 786\u2013789 (2008).","journal-title":"Arch. Neurol."},{"key":"1171_CR161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000615","volume":"5","author":"M Garcia","year":"2009","unstructured":"Garcia, M. et al. Phosphofructo-1-kinase deficiency leads to a severe cardiac and hematological disorder in addition to skeletal muscle glycogenosis. PLoS Genet. 5, e1000615 (2009).","journal-title":"PLoS Genet."},{"key":"1171_CR162","first-page":"105","volume":"26","author":"A Toscano","year":"2007","unstructured":"Toscano, A. & Musumeci, O. Tarui disease and distal glycogenoses: clinical and genetic update. Acta Myol. 26, 105\u2013107 (2007).","journal-title":"Acta Myol."},{"key":"1171_CR163","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000112406","volume":"110","author":"J Finsterer","year":"2008","unstructured":"Finsterer, J. & Stollberger, C. Progressive mitral valve thickening and progressive muscle cramps as manifestations of glycogenosis VII (Tarui\u2019s disease). Cardiology 110, 238\u2013240 (2008).","journal-title":"Cardiology"},{"key":"1171_CR164","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/mus.880150406","volume":"15","author":"R Amit","year":"1992","unstructured":"Amit, R. et al. Fatal familial infantile glycogen storage disease: multisystem phosphofructokinase deficiency. Muscle Nerve 15, 455\u2013458 (1992).","journal-title":"Muscle Nerve"},{"key":"1171_CR165","volume":"24","author":"C Lefeuvre","year":"2020","unstructured":"Lefeuvre, C. et al. Glycogenin-1 deficiency mimicking limb-girdle muscular dystrophy. Mol. Genet. Metab. Rep. 24, 100597 (2020).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1171_CR166","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ana.24284","volume":"76","author":"E Malfatti","year":"2014","unstructured":"Malfatti, E. et al. A new muscle glycogen storage disease associated with glycogenin-1 deficiency. Ann. Neurol. 76, 891\u2013898 (2014).","journal-title":"Ann. Neurol."},{"key":"1171_CR167","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa0900661","volume":"362","author":"AR Moslemi","year":"2010","unstructured":"Moslemi, A. R. et al. Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. N. Engl. J. Med. 362, 1203\u20131210 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1171_CR168","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10545-016-9978-1","volume":"40","author":"C Hedberg-Oldfors","year":"2017","unstructured":"Hedberg-Oldfors, C. et al. Cardiomyopathy as presenting sign of glycogenin-1 deficiency-report of three cases and review of the literature. J. Inherit. Metab. Dis. 40, 139\u2013149 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR169","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.recesp.2020.05.033","volume":"74","author":"N Mancheno","year":"2021","unstructured":"Mancheno, N. et al. Cardiac phenotype in glycogen storage disease type XV: a rare cardiomyopathy to bear in mind. Rev. Esp. Cardiol. 74, 99\u2013101 (2021).","journal-title":"Rev. Esp. Cardiol."},{"key":"1171_CR170","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cmet.2017.06.008","volume":"26","author":"G Testoni","year":"2017","unstructured":"Testoni, G. et al. Lack of glycogenin causes glycogen accumulation and muscle function impairment. Cell Metab. 26, 256\u2013266.e4 (2017).","journal-title":"Cell Metab."},{"key":"1171_CR171","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00001573-200205000-00004","volume":"17","author":"MH Gollob","year":"2002","unstructured":"Gollob, M. H., Green, M. S., Tang, A. S. & Roberts, R. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr. Opin. Cardiol. 17, 229\u2013234 (2002).","journal-title":"Curr. Opin. Cardiol."},{"key":"1171_CR172","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1172\/JCI118154","volume":"96","author":"CA MacRae","year":"1995","unstructured":"MacRae, C. A. et al. Familial hypertrophic cardiomyopathy with Wolff\u2013Parkinson\u2013White syndrome maps to a locus on chromosome 7q3. J. Clin. Invest. 96, 1216\u20131220 (1995).","journal-title":"J. Clin. Invest."},{"key":"1171_CR173","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJM200106143442403","volume":"344","author":"MH Gollob","year":"2001","unstructured":"Gollob, M. H. et al. Identification of a gene responsible for familial Wolff\u2013Parkinson\u2013White syndrome. N. Engl. J. Med. 344, 1823\u20131831 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1171_CR174","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1172\/JCI0214571","volume":"109","author":"M Arad","year":"2002","unstructured":"Arad, M. et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest. 109, 357\u2013362 (2002).","journal-title":"J. Clin. Invest."},{"key":"1171_CR175","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2004.11.053","volume":"45","author":"RT Murphy","year":"2005","unstructured":"Murphy, R. T. et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff\u2013Parkinson\u2013White syndrome: natural history. J. Am. Coll. Cardiol. 45, 922\u2013930 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1171_CR176","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa033349","volume":"352","author":"M Arad","year":"2005","unstructured":"Arad, M. et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N. Engl. J. Med. 352, 362\u2013372 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1171_CR177","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/CIRCGENETICS.110.958835","volume":"4","author":"C Gruner","year":"2011","unstructured":"Gruner, C. et al. Sarcomere protein gene mutations in patients with apical hypertrophic cardiomyopathy. Circ. Cardiovasc. Genet. 4, 288\u2013295 (2011).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"1171_CR178","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.hrthm.2010.09.081","volume":"8","author":"EB Sternick","year":"2011","unstructured":"Sternick, E. B. et al. Clinical, electrocardiographic, and electrophysiologic characteristics of patients with a fasciculoventricular pathway: the role of PRKAG2 mutation. Heart Rhythm. 8, 58\u201364 (2011).","journal-title":"Heart Rhythm."},{"key":"1171_CR179","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jelectrocard.2010.02.009","volume":"44","author":"LP Zhang","year":"2011","unstructured":"Zhang, L. P., Hui, B. & Gao, B. R. High risk of sudden death associated with a PRKAG2-related familial Wolff\u2013Parkinson\u2013White syndrome. J. Electrocardiol. 44, 483\u2013486 (2011).","journal-title":"J. Electrocardiol."},{"key":"1171_CR180","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12968-015-0192-3","volume":"17","author":"P P\u00f6yh\u00f6nen","year":"2015","unstructured":"P\u00f6yh\u00f6nen, P. et al. Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations. J. Cardiovasc. Magn. Reson. 17, 89 (2015).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"1171_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-017-0512-6","volume":"19","author":"P Banankhah","year":"2018","unstructured":"Banankhah, P., Fishbein, G. A., Dota, A. & Ardehali, R. Cardiac manifestations of PRKAG2 mutation. BMC Med. Genet. 19, 1 (2018).","journal-title":"BMC Med. Genet."},{"key":"1171_CR182","first-page":"651","volume":"19","author":"J Thevenon","year":"2017","unstructured":"Thevenon, J. et al. High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations. Europace 19, 651\u2013659 (2017).","journal-title":"Europace"},{"key":"1171_CR183","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jacc.2020.05.029","volume":"76","author":"A Lopez-Sainz","year":"2020","unstructured":"Lopez-Sainz, A. et al. Clinical features and natural history of PRKAG2 variant cardiac glycogenosis. J. Am. Coll. Cardiol. 76, 186\u2013197 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1171_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77124-9","volume":"10","author":"H Ahamed","year":"2020","unstructured":"Ahamed, H. et al. Phenotypic expression and clinical outcomes in a South Asian PRKAG2 cardiomyopathy cohort. Sci. Rep. 10, 20610 (2020).","journal-title":"Sci. Rep."},{"key":"1171_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102723","volume":"54","author":"D Hu","year":"2020","unstructured":"Hu, D. et al. Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease. EBioMedicine 54, 102723 (2020).","journal-title":"EBioMedicine"},{"key":"1171_CR186","doi-asserted-by":"publisher","first-page":"eAO0549","DOI":"10.31744\/einstein_journal\/2024AO0549","volume":"22","author":"LP van der Steld","year":"2024","unstructured":"van der Steld, L. P. et al. PRKAG2 syndrome, a rare hypertrophic cardiomyopathy: a Brazilian long-term follow-up with extracardiac disorders. Einstein 22, eAO0549 (2024).","journal-title":"Einstein"},{"key":"1171_CR187","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.115.003121","volume":"9","author":"AG Porto","year":"2016","unstructured":"Porto, A. G. et al. Clinical spectrum of PRKAG2 syndrome. Circ. Arrhythm. Electrophysiol. 9, e003121 (2016).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"1171_CR188","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13000-021-01100-8","volume":"16","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. Danon disease: a case report and literature review. Diagn. Pathol. 16, 39 (2021).","journal-title":"Diagn. Pathol."},{"key":"1171_CR189","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","volume":"7","author":"RS D\u2019Souza","year":"2014","unstructured":"D\u2019Souza, R. S. et al. Danon disease: clinical features, evaluation, and management. Circ. Heart Fail. 7, 843\u2013849 (2014).","journal-title":"Circ. Heart Fail."},{"key":"1171_CR190","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1212\/WNL.31.1.51","volume":"31","author":"MJ Danon","year":"1981","unstructured":"Danon, M. J. et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 31, 51\u201357 (1981).","journal-title":"Neurology"},{"key":"1171_CR191","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/35022604","volume":"406","author":"I Nishino","year":"2000","unstructured":"Nishino, I. et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406, 906\u2013910 (2000).","journal-title":"Nature"},{"key":"1171_CR192","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1242\/jcs.184770","volume":"129","author":"TJ Rowland","year":"2016","unstructured":"Rowland, T. J., Sweet, M. E., Mestroni, L. & Taylor, M. R. Danon disease \u2013 dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J. Cell Sci. 129, 2135\u20132143 (2016).","journal-title":"J. Cell Sci."},{"key":"1171_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.475","volume":"8","author":"AC Nascimbeni","year":"2017","unstructured":"Nascimbeni, A. C., Fanin, M., Angelini, C. & Sandri, M. Autophagy dysregulation in Danon disease. Cell Death Dis. 8, e2565 (2017).","journal-title":"Cell Death Dis."},{"key":"1171_CR194","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jama.2009.371","volume":"301","author":"BJ Maron","year":"2009","unstructured":"Maron, B. J. et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301, 1253\u20131259 (2009).","journal-title":"JAMA"},{"key":"1171_CR195","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","volume":"13","author":"D Boucek","year":"2011","unstructured":"Boucek, D., Jirikowic, J. & Taylor, M. Natural history of Danon disease. Genet. Med. 13, 563\u2013568 (2011).","journal-title":"Genet. Med."},{"key":"1171_CR196","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0960-8966(02)00179-7","volume":"12","author":"L Lacoste-Collin","year":"2002","unstructured":"Lacoste-Collin, L. et al. Danon\u2019s disease (X-linked vacuolar cardiomyopathy and myopathy): a case with a novel Lamp-2 gene mutation. Neuromuscul. Disord. 12, 882\u2013885 (2002).","journal-title":"Neuromuscul. Disord."},{"key":"1171_CR197","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/mus.20471","volume":"33","author":"A Echaniz-Laguna","year":"2006","unstructured":"Echaniz-Laguna, A. et al. Novel Lamp-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease. Muscle Nerve 33, 393\u2013397 (2006).","journal-title":"Muscle Nerve"},{"key":"1171_CR198","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.nmd.2004.12.007","volume":"15","author":"JA Lobrinus","year":"2005","unstructured":"Lobrinus, J. A. et al. Morphological, clinical and genetic aspects in a family with a novel LAMP-2 gene mutation (Danon disease). Neuromuscul. Disord. 15, 293\u2013298 (2005).","journal-title":"Neuromuscul. Disord."},{"key":"1171_CR199","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.105.546481","volume":"112","author":"Z Yang","year":"2005","unstructured":"Yang, Z. et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 112, 1612\u20131617 (2005).","journal-title":"Circulation"},{"key":"1171_CR200","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/hrt.2003.029504","volume":"90","author":"P Charron","year":"2004","unstructured":"Charron, P. et al. Danon\u2019s disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 90, 842\u2013846 (2004).","journal-title":"Heart"},{"key":"1171_CR201","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00431-005-1678-z","volume":"164","author":"C Balmer","year":"2005","unstructured":"Balmer, C. et al. Familial X-linked cardiomyopathy (Danon disease): diagnostic confirmation by mutation analysis of the LAMP2 gene. Eur. J. Pediatr. 164, 509\u2013514 (2005).","journal-title":"Eur. J. Pediatr."},{"key":"1171_CR202","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1007\/s10545-009-1097-9","volume":"32","author":"G Regelsberger","year":"2009","unstructured":"Regelsberger, G. et al. Danon disease: case report and detection of new mutation. J. Inherit. Metab. Dis. 32, S115\u2013S122 (2009).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR203","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1253\/circj.CJ-08-0241","volume":"73","author":"N Dougu","year":"2009","unstructured":"Dougu, N. et al. Novel LAMP-2 mutation in a family with Danon disease presenting with hypertrophic cardiomyopathy. Circ. J. 73, 376\u2013380 (2009).","journal-title":"Circ. J."},{"key":"1171_CR204","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mus.21252","volume":"39","author":"F Sabourdy","year":"2009","unstructured":"Sabourdy, F. et al. Danon disease: further clinical and molecular heterogeneity. Muscle Nerve 39, 837\u2013844 (2009).","journal-title":"Muscle Nerve"},{"key":"1171_CR205","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/mus.20930","volume":"37","author":"A Nadeau","year":"2008","unstructured":"Nadeau, A., Therrien, C., Karpati, G. & Sinnreich, M. Danon disease due to a novel splice mutation in the LAMP2 gene. Muscle Nerve 37, 338\u2013342 (2008).","journal-title":"Muscle Nerve"},{"key":"1171_CR206","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.nmd.2005.02.008","volume":"15","author":"O Musumeci","year":"2005","unstructured":"Musumeci, O. et al. Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene. Neuromuscul. Disord. 15, 409\u2013411 (2005).","journal-title":"Neuromuscul. Disord."},{"key":"1171_CR207","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.nmd.2008.09.008","volume":"18","author":"C Di Blasi","year":"2008","unstructured":"Di Blasi, C., Jarre, L., Blasevich, F., Dassi, P. & Mora, M. Danon disease: a novel LAMP2 mutation affecting the pre-mRNA splicing and causing aberrant transcripts and partial protein expression. Neuromuscul. Disord. 18, 962\u2013966 (2008).","journal-title":"Neuromuscul. Disord."},{"key":"1171_CR208","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1212\/WNL.58.12.1773","volume":"58","author":"K Sugie","year":"2002","unstructured":"Sugie, K. et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 58, 1773\u20131778 (2002).","journal-title":"Neurology"},{"key":"1171_CR209","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijcard.2019.01.020","volume":"286","author":"M Brambatti","year":"2019","unstructured":"Brambatti, M. et al. Danon disease: gender differences in presentation and outcomes. Int. J. Cardiol. 286, 92\u201398 (2019).","journal-title":"Int. J. Cardiol."},{"key":"1171_CR210","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott, P. M. et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 35, 2733\u20132779 (2014).","journal-title":"Eur. Heart J."},{"key":"1171_CR211","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen, S. R. et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 76, 3022\u20133055 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1171_CR212","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi, C. et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 34, 1448\u20131458 (2013).","journal-title":"Eur. Heart J."},{"key":"1171_CR213","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jacc.2023.08.014","volume":"82","author":"KN Hong","year":"2023","unstructured":"Hong, K. N. et al. International consensus on differential diagnosis and management of patients with Danon disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 82, 1628\u20131647 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1171_CR214","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2022.03.050","volume":"357","author":"G Limongelli","year":"2022","unstructured":"Limongelli, G. et al. Diagnosis and management of rare cardiomyopathies in adult and paediatric patients. A position paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP). Int. J. Cardiol. 357, 55\u201371 (2022).","journal-title":"Int. J. Cardiol."},{"key":"1171_CR215","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.cardfail.2021.11.007","volume":"28","author":"KN Hong","year":"2022","unstructured":"Hong, K. N. et al. Cardiac transplantation in Danon disease. J. Card. Fail. 28, 664\u2013669 (2022).","journal-title":"J. Card. Fail."},{"key":"1171_CR216","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/jimd.12654","volume":"47","author":"DD Koeberl","year":"2024","unstructured":"Koeberl, D. D. et al. Gene therapy for glycogen storage diseases. J. Inherit. Metab. Dis. 47, 93\u2013118 (2024).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1171_CR217","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax1744","volume":"12","author":"AM Manso","year":"2020","unstructured":"Manso, A. M. et al. Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease. Sci. Transl. Med. 12, eaax1744 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1171_CR218","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","volume":"392","author":"B Greenberg","year":"2025","unstructured":"Greenberg, B. et al. Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N. Engl. J. Med. 392, 972\u2013983 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1171_CR219","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01562-x","volume":"15","author":"RS Scalco","year":"2020","unstructured":"Scalco, R. S. et al. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC). Orphanet J. Rare Dis. 15, 330 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"1171_CR220","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41572-023-00456-z","volume":"9","author":"WB Hannah","year":"2023","unstructured":"Hannah, W. B. et al. Glycogen storage diseases. Nat. Rev. Dis. Prim. 9, 46 (2023).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1171_CR221","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"1171_CR222","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1136\/bmj.1.5033.1431","volume":"1","author":"FG Young","year":"1957","unstructured":"Young, F. G. Claude Bernard and the discovery of glycogen; a century of retrospect. Br. Med. J. 1, 1431\u20131437 (1957).","journal-title":"Br. Med. J."},{"key":"1171_CR223","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0021-9258(18)44198-1","volume":"276","author":"A Kornberg","year":"2001","unstructured":"Kornberg, A. Remembering our teachers. J. Biol. Chem. 276, 3\u201311 (2001).","journal-title":"J. Biol. Chem."},{"key":"1171_CR224","first-page":"497","volume":"82","author":"E Von Gierke","year":"1929","unstructured":"Von Gierke, E. Hepato-nephro-megalia glycogenica (Glykogenspeicher-krankheit der Leber und Nieren). Beitr. Pathol. Anat. 82, 497\u2013513 (1929).","journal-title":"Beitr. Pathol. Anat."},{"key":"1171_CR225","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1515\/bchm2.1929.182.3-4.148","volume":"182","author":"R Sch\u00f6nheimer","year":"1929","unstructured":"Sch\u00f6nheimer, R. \u00dcber eine eigenartige St\u00f6rung des Kohlehydrat-Stoffwechsels [German]. Hoppe Seylers Z. Physiol. Chem. 182, 148\u2013150 (1929).","journal-title":"Hoppe Seylers Z. Physiol. Chem."},{"key":"1171_CR226","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0021-9258(18)38504-1","volume":"199","author":"GT Cori","year":"1952","unstructured":"Cori, G. T. & Cori, C. F. Glucose-6-phosphatase of the liver in glycogen storage disease. J. Biol. Chem. 199, 661\u2013667 (1952).","journal-title":"J. Biol. Chem."},{"key":"1171_CR227","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3181\/00379727-34-8759P","volume":"34","author":"CF Cori","year":"1936","unstructured":"Cori, C. F. & Cori, G. T. Mechanism of formation of hexosemonophosphate in muscle and isolation of a new phosphate ester. Proc. Soc. Exp. Biol. Med. 34, 702\u2013705 (1936).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"1171_CR228","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","volume":"6","author":"JA Lim","year":"2014","unstructured":"Lim, J. A., Li, L. & Raben, N. Pompe disease: from pathophysiology to therapy and back again. Front. Aging Neurosci. 6, 177 (2014).","journal-title":"Front. Aging Neurosci."},{"key":"1171_CR229","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/BF02248461","volume":"52","author":"G Bischoff","year":"1932","unstructured":"Bischoff, G. Zum klinischen Bild der Glykogen-Speicherungskrankheit (Glykogenose) [German]. Z. Kinderheilkd. 52, 722\u2013726 (1932).","journal-title":"Z. Kinderheilkd."},{"key":"1171_CR230","first-page":"222","volume":"90","author":"W Putschar","year":"1932","unstructured":"Putschar, W. Glykogenspeicherkrankheit des Herzens: \u201cThesaurismosis glycogenica\u201d (v. Gierke) [German]. Beitr. Pathol. Anat. 90, 222\u2013232 (1932).","journal-title":"Beitr. Pathol. Anat."},{"key":"1171_CR231","first-page":"38","volume":"10","author":"GT Cori","year":"1954","unstructured":"Cori, G. T. Enzymes and glycogen structure in glycogenosis. Osterr Z. Kinderheilkd. Kinderfuersorge 10, 38\u201342 (1954).","journal-title":"Osterr Z. Kinderheilkd. Kinderfuersorge"},{"key":"1171_CR232","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1042\/bj0860011","volume":"86","author":"HG Hers","year":"1963","unstructured":"Hers, H. G. \u03b1-Glucosidase deficiency in generalized glycogen-storage disease (Pompe\u2019s disease). Biochem. J. 86, 11\u201316 (1963).","journal-title":"Biochem. J."},{"key":"1171_CR233","doi-asserted-by":"publisher","first-page":"9621","DOI":"10.3390\/ijms21249621","volume":"21","author":"A Almodovar-Paya","year":"2020","unstructured":"Almodovar-Paya, A. et al. Preclinical research in glycogen storage diseases: a comprehensive review of current animal models. Int. J. Mol. Sci. 21, 9621 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1171_CR234","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/hmg\/7.1.53","volume":"7","author":"AG Bijvoet","year":"1998","unstructured":"Bijvoet, A. G. et al. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum. Mol. Genet. 7, 53\u201362 (1998).","journal-title":"Hum. Mol. Genet."},{"key":"1171_CR235","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1751-0813.1981.tb02666.x","volume":"57","author":"BM O\u2019Sullivan","year":"1981","unstructured":"O\u2019Sullivan, B. M. et al. Generalised glycogenosis in Brahman cattle. Aust. Vet. J. 57, 227\u2013229 (1981).","journal-title":"Aust. Vet. J."},{"key":"1171_CR236","first-page":"475","volume":"29","author":"H Murakami","year":"1980","unstructured":"Murakami, H., Takagi, A., Nanaka, S., Ishiura, S. & Sugita, H. Glycogenosis II in Japanese quails. Jikken Dobutsu 29, 475\u2013478 (1980).","journal-title":"Jikken Dobutsu"},{"key":"1171_CR237","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/01.CIR.96.2.676","volume":"96","author":"MF Allard","year":"1997","unstructured":"Allard, M. F. et al. Glycogen metabolism in the aerobic hypertrophied rat heart. Circulation 96, 676\u2013682 (1997).","journal-title":"Circulation"},{"key":"1171_CR238","first-page":"H1239","volume":"274","author":"GW Goodwin","year":"1998","unstructured":"Goodwin, G. W., Ahmad, F., Doenst, T. & Taegtmeyer, H. Energy provision from glycogen, glucose, and fatty acids on adrenergic stimulation of isolated working rat hearts. Am. J. Physiol. 274, H1239\u2013H1247 (1998).","journal-title":"Am. J. Physiol."},{"key":"1171_CR239","doi-asserted-by":"publisher","first-page":"29530","DOI":"10.1074\/jbc.273.45.29530","volume":"273","author":"GW Goodwin","year":"1998","unstructured":"Goodwin, G. W., Taylor, C. S. & Taegtmeyer, H. Regulation of energy metabolism of the heart during acute increase in heart work. J. Biol. Chem. 273, 29530\u201329539 (1998).","journal-title":"J. Biol. Chem."},{"key":"1171_CR240","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1161\/01.CIR.93.8.1549","volume":"93","author":"SL Henning","year":"1996","unstructured":"Henning, S. L., Wambolt, R. B., Schonekess, B. O., Lopaschuk, G. D. & Allard, M. F. Contribution of glycogen to aerobic myocardial glucose utilization. Circulation 93, 1549\u20131555 (1996).","journal-title":"Circulation"},{"key":"1171_CR241","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10974-019-09557-3","volume":"42","author":"J Nielsen","year":"2021","unstructured":"Nielsen, J., Johnsen, J., Pryds, K., Ortenblad, N. & Botker, H. E. Myocardial subcellular glycogen distribution and sarcoplasmic reticulum Ca2+ handling: effects of ischaemia, reperfusion and ischaemic preconditioning. J. Muscle Res. Cell Motil. 42, 17\u201331 (2021).","journal-title":"J. Muscle Res. Cell Motil."},{"key":"1171_CR242","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1161\/01.CIR.99.4.578","volume":"99","author":"C Depre","year":"1999","unstructured":"Depre, C., Vanoverschelde, J. L. & Taegtmeyer, H. Glucose for the heart. Circulation 99, 578\u2013588 (1999).","journal-title":"Circulation"},{"key":"1171_CR243","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cvr\/28.4.524","volume":"28","author":"HE Botker","year":"1994","unstructured":"Botker, H. E., Helligso, P., Kimose, H. H., Thomassen, A. R. & Nielsen, T. T. Determination of high energy phosphates and glycogen in cardiac and skeletal muscle biopsies, with special reference to influence of biopsy technique and delayed freezing. Cardiovasc. Res. 28, 524\u2013527 (1994).","journal-title":"Cardiovasc. Res."},{"key":"1171_CR244","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/oxfordjournals.bmb.a069888","volume":"17","author":"HJ Shelley","year":"1961","unstructured":"Shelley, H. J. Glycogen reserves and their changes at birth and in anoxia. Br. Med. Bull. 17, 137\u2013143 (1961).","journal-title":"Br. Med. Bull."},{"key":"1171_CR245","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.yjmcc.2013.09.014","volume":"65","author":"ME Reichelt","year":"2013","unstructured":"Reichelt, M. E., Mellor, K. M., Curl, C. L., Stapleton, D. & Delbridge, L. M. Myocardial glycophagy \u2013 a specific glycogen handling response to metabolic stress is accentuated in the female heart. J. Mol. Cell Cardiol. 65, 67\u201375 (2013).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1171_CR246","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1152\/jappl.1986.60.4.1268","volume":"60","author":"AH Goldfarb","year":"1986","unstructured":"Goldfarb, A. H., Bruno, J. F. & Buckenmeyer, P. J. Intensity and duration effects of exercise on heart cAMP, phosphorylase, and glycogen. J. Appl. Physiol. 60, 1268\u20131273 (1986).","journal-title":"J. Appl. Physiol."},{"key":"1171_CR247","first-page":"H542","volume":"260","author":"CA Schneider","year":"1991","unstructured":"Schneider, C. A., Nguyen, V. T. & Taegtmeyer, H. Feeding and fasting determine postischemic glucose utilization in isolated working rat hearts. Am. J. Physiol. 260, H542\u2013H548 (1991).","journal-title":"Am. J. Physiol."},{"key":"1171_CR248","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1152\/ajplegacy.1975.229.2.398","volume":"229","author":"LD Segel","year":"1975","unstructured":"Segel, L. D., Chung, A., Mason, D. T. & Amsterdam, E. A. Cardiac glycogen in long-evans rats: diurnal pattern and response to exercise. Am. J. Physiol. 229, 398\u2013401 (1975).","journal-title":"Am. J. Physiol."},{"key":"1171_CR249","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/0300-9629(73)90076-5","volume":"45","author":"D Kerem","year":"1973","unstructured":"Kerem, D., Hammond, D. D. & Elsner, R. Tissue glycogen levels in the Weddell seal, Leptonychotes weddelli: a possible adaptation to asphyxial hypoxia. Comp. Biochem. Physiol. A Comp. Physiol. 45, 731\u2013736 (1973).","journal-title":"Comp. Biochem. Physiol. A Comp. Physiol."},{"key":"1171_CR250","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yjmcc.2024.02.009","volume":"189","author":"KM Mellor","year":"2024","unstructured":"Mellor, K. M. et al. Myocardial glycophagy flux dysregulation and glycogen accumulation characterize diabetic cardiomyopathy. J. Mol. Cell Cardiol. 189, 83\u201389 (2024).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1171_CR251","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1139\/o83-027","volume":"61","author":"BR Bhavnani","year":"1983","unstructured":"Bhavnani, B. R. Ontogeny of some enzymes of glycogen metabolism in rabbit fetal heart, lungs, and liver. Can. J. Biochem. Cell Biol. 61, 191\u2013197 (1983).","journal-title":"Can. J. Biochem. Cell Biol."},{"key":"1171_CR252","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000243363","volume":"59","author":"J Gutierrez-Correa","year":"1991","unstructured":"Gutierrez-Correa, J., Hod, M., Passoneau, J. V. & Freinkel, N. Glycogen and enzymes of glycogen metabolism in rat embryos and fetal organs. Biol. Neonate 59, 294\u2013302 (1991).","journal-title":"Biol. Neonate"},{"key":"1171_CR253","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1042\/BJ20111416","volume":"441","author":"PJ Roach","year":"2012","unstructured":"Roach, P. J., Depaoli-Roach, A. A., Hurley, T. D. & Tagliabracci, V. S. Glycogen and its metabolism: some new developments and old themes. Biochem. J. 441, 763\u2013787 (2012).","journal-title":"Biochem. J."},{"key":"1171_CR254","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrcardio.2017.35","volume":"14","author":"LMD Delbridge","year":"2017","unstructured":"Delbridge, L. M. D., Mellor, K. M., Taylor, D. J. & Gottlieb, R. A. Myocardial stress and autophagy: mechanisms and potential therapies. Nat. Rev. Cardiol. 14, 412\u2013425 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"1171_CR255","doi-asserted-by":"publisher","first-page":"H1194","DOI":"10.1152\/ajpheart.00002.2015","volume":"308","author":"LM Delbridge","year":"2015","unstructured":"Delbridge, L. M., Mellor, K. M., Taylor, D. J. & Gottlieb, R. A. Myocardial autophagic energy stress responses \u2013 macroautophagy, mitophagy, and glycophagy. Am. J. Physiol. Heart Circ. Physiol. 308, H1194\u2013H1204 (2015).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1171_CR256","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.cca.2018.06.014","volume":"484","author":"H Zhao","year":"2018","unstructured":"Zhao, H., Tang, M., Liu, M. & Chen, L. Glycophagy: an emerging target in pathology. Clin. Chim. Acta 484, 298\u2013303 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"1171_CR257","first-page":"489","volume":"35","author":"J Caulfield","year":"1959","unstructured":"Caulfield, J. & Klionsky, B. Myocardial ischemia and early infarction: an electron microscopic study. Am. J. Pathol. 35, 489\u2013523 (1959).","journal-title":"Am. J. Pathol."},{"key":"1171_CR258","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202113071","volume":"154","author":"J Nielsen","year":"2022","unstructured":"Nielsen, J., Dubillot, P., Stausholm, M. H. & Ortenblad, N. Specific ATPases drive compartmentalized glycogen utilization in rat skeletal muscle. J. Gen. Physiol. 154, e202113071 (2022).","journal-title":"J. Gen. Physiol."},{"key":"1171_CR259","doi-asserted-by":"crossref","unstructured":"Bers, D. M. Excitation-contraction coupling and cardiac contractile force 2nd edn (Springer, 2001) [Series Developments in Cardiovascular Medicine Vol. 237].","DOI":"10.1007\/978-94-010-0658-3"},{"key":"1171_CR260","first-page":"H1082","volume":"274","author":"J Dizon","year":"1998","unstructured":"Dizon, J. et al. Metabolic inhibition in the perfused rat heart: evidence for glycolytic requirement for normal sodium homeostasis. Am. J. Physiol. 274, H1082\u2013H1089 (1998).","journal-title":"Am. J. Physiol."},{"key":"1171_CR261","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1161\/01.RES.54.5.536","volume":"54","author":"T Geisbuhler","year":"1984","unstructured":"Geisbuhler, T. et al. Adenine nucleotide metabolism and compartmentalization in isolated adult rat heart cells. Circ. Res. 54, 536\u2013546 (1984).","journal-title":"Circ. Res."},{"key":"1171_CR262","first-page":"509","volume":"11","author":"OL Bricknell","year":"1976","unstructured":"Bricknell, O. L. & Opie, L. H. Glycolytic ATP and its production during ischemia in isolated Langendorff-perfused rat hearts. Recent. Adv. Stud. Card. Struct. Metab. 11, 509\u2013519 (1976).","journal-title":"Recent. Adv. Stud. Card. Struct. Metab."},{"key":"1171_CR263","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1085\/jgp.78.5.547","volume":"78","author":"RW Mercer","year":"1981","unstructured":"Mercer, R. W. & Dunham, P. B. Membrane-bound ATP fuels the Na\/K pump. Studies on membrane-bound glycolytic enzymes on inside-out vesicles from human red cell membranes. J. Gen. Physiol. 78, 547\u2013568 (1981).","journal-title":"J. Gen. Physiol."},{"key":"1171_CR264","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1113\/jphysiol.1992.sp018991","volume":"447","author":"JD Campbell","year":"1992","unstructured":"Campbell, J. D. & Paul, R. J. The nature of fuel provision for the Na+,K+-ATPase in porcine vascular smooth muscle. J. Physiol. 447, 67\u201382 (1992).","journal-title":"J. Physiol."},{"key":"1171_CR265","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/0005-2736(81)90160-7","volume":"649","author":"ET Fossel","year":"1981","unstructured":"Fossel, E. T. & Solomon, A. K. Relation between red cell membrane (Na+ + K+)-ATPase and band 3 protein. Biochim. Biophys. Acta 649, 557\u2013571 (1981).","journal-title":"Biochim. Biophys. Acta"},{"key":"1171_CR266","doi-asserted-by":"publisher","first-page":"35176","DOI":"10.1074\/jbc.M402282200","volume":"279","author":"P Singh","year":"2004","unstructured":"Singh, P., Salih, M., Leddy, J. J. & Tuana, B. S. The muscle-specific calmodulin-dependent protein kinase assembles with the glycolytic enzyme complex at the sarcoplasmic reticulum and modulates the activity of glyceraldehyde-3-phosphate dehydrogenase in a Ca2+\/calmodulin-dependent manner. J. Biol. Chem. 279, 35176\u201335182 (2004).","journal-title":"J. Biol. Chem."},{"key":"1171_CR267","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1006\/jmcc.2000.1130","volume":"32","author":"E Boehm","year":"2000","unstructured":"Boehm, E., Ventura-Clapier, R., Mateo, P., Lechene, P. & Veksler, V. Glycolysis supports calcium uptake by the sarcoplasmic reticulum in skinned ventricular fibres of mice deficient in mitochondrial and cytosolic creatine kinase. J. Mol. Cell Cardiol. 32, 891\u2013902 (2000).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1171_CR268","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1253\/jcj.65.1064","volume":"65","author":"K Takeuchi","year":"2001","unstructured":"Takeuchi, K. et al. Improving glucose metabolism and\/or sarcoplasmic reticulum Ca2+-ATPase function is warranted for immature pressure overload hypertrophied myocardium. Jpn. Circ. J. 65, 1064\u20131070 (2001).","journal-title":"Jpn. Circ. J."},{"key":"1171_CR269","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1113\/jphysiol.2006.117242","volume":"577","author":"AV Zima","year":"2006","unstructured":"Zima, A. V., Kockskamper, J. & Blatter, L. A. Cytosolic energy reserves determine the effect of glycolytic sugar phosphates on sarcoplasmic reticulum Ca2+ release in cat ventricular myocytes. J. Physiol. 577, 281\u2013293 (2006).","journal-title":"J. Physiol."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01171-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01171-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01171-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:02:24Z","timestamp":1764777744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01171-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":269,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1038\/s41569-025-01171-w","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"12 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.M.C. has received speaker\u2019s fees from Janssen Oncology. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}